The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
News|Videos|December 15, 2017
Treatment of Challenging Mantle Cell Lymphoma Cases
Author(s)Peter Martin, MD
This video reviews the treatment of mantle cell lymphoma cases that do not fit the typical mold.
Advertisement
In this video, Peter Martin, MD, of Weill Cornell Medicine in New York, discusses the treatment of mantle cell lymphoma cases that do not fit the typical mold.
Martin gave a presentation on this topic during an education session at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition, held December 9–12 in Atlanta.
Advertisement
Related to this article
Developers have resubmitted the biologics license application for tabelecleucel following feedback from a Type A meeting in April 2026.
“To me, the biggest differentiator might be how the patient wants to experience care,” said Krish Patel, MD, on treatment options for patients with lymphoma.
Data from the phase BRUIN CLL-313 and BRUIN CLL-314 trials support the approval of pirtobrutinib for patients with CLL or SLL in China.
![“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/c7abebf9344f9b1be9aee80d9879d139c1655bcc-1200x1197.jpg?w=350&fit=crop&auto=format)
“We should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.
Health Canada approved epcoritamab plus lenalidomide and rituximab for relapsed/refractory grade 1 to 3a follicular lymphoma, backed by the EPCORE FL-1 trial.
Meletios A. Dimopoulos, MD, explored how anselamimab’s benefit in kappa light chain amyloidosis fits into the evolving role of anti-fibril therapy.
Meletios A. Dimopoulos, MD, discussed where bispecific antibodies such as teclistamab may fit for patients with relapsed Waldenström macroglobulinemia.
Advertisement
Advertisement
Trending on CancerNetwork
1
From Accelerated Approval to Reapproval of Belantamab Mafodotin
2
DREAMM-7 Study Design and the Rationale
3
EXCALIBER-RRMM: Iberdomide in Relapsed/Refractory Multiple Myeloma
4
Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer
5